Jiangsu Nhwa Pharmaceutical Co Ltd Total Assets
Jiangsu Nhwa Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) holds total assets worth CN¥9.54 Billion CNY (≈ $1.40 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Jiangsu Nhwa Pharmaceutical Co Ltd for the company's overall valuation and market capitalisation.
Total Assets of Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2025)
Total assets of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2025. This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See latest Jiangsu Nhwa Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.
Jiangsu Nhwa Pharmaceutical Co Ltd - Asset Composition Analysis
Jiangsu Nhwa Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Jiangsu Nhwa Pharmaceutical Co Ltd total assets breakdown as of December 2025. Jiangsu Nhwa Pharmaceutical Co Ltd's total assets of CN¥9.54 Billion consist of 70.1% current assets and 29.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.7% |
| Accounts Receivable | CN¥1.47 Billion | 16.0% |
| Inventory | CN¥756.78 Million | 8.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥557.84 Million | 6.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Jiangsu Nhwa Pharmaceutical Co Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Nhwa Pharmaceutical Co Ltd's current assets represent 70.1% of total assets in 2025, an increase from 68.3% in 2005.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2025, up from 13.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 5.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 16.0% of total assets.
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangsu Nhwa Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Jiangsu Nhwa Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.22 | 6.05 | 6.94 |
| Quick Ratio | 5.43 | 5.34 | 5.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥5.65 Billion | CN¥5.32 Billion | CN¥3.27 Billion |
Jiangsu Nhwa Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu Nhwa Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.66 |
| Latest Market Cap to Assets Ratio | 0.37 |
| Asset Growth Rate (YoY) | 9.3% |
| Total Assets | CN¥9.22 Billion |
| Market Capitalization | $3.38 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Nhwa Pharmaceutical Co Ltd's assets below their book value (0.37x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jiangsu Nhwa Pharmaceutical Co Ltd's assets grew by 9.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2025)
The table below shows the annual total assets of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥9.22 Billion ≈ $1.35 Billion |
+9.28% |
| 2024-12-31 | CN¥8.44 Billion ≈ $1.24 Billion |
+15.17% |
| 2023-12-31 | CN¥7.33 Billion ≈ $1.07 Billion |
+13.07% |
| 2022-12-31 | CN¥6.48 Billion ≈ $948.40 Million |
+13.76% |
| 2021-12-31 | CN¥5.70 Billion ≈ $833.68 Million |
+18.39% |
| 2020-12-31 | CN¥4.81 Billion ≈ $704.17 Million |
+14.53% |
| 2019-12-31 | CN¥4.20 Billion ≈ $614.81 Million |
+4.18% |
| 2018-12-31 | CN¥4.03 Billion ≈ $590.13 Million |
+22.15% |
| 2017-12-31 | CN¥3.30 Billion ≈ $483.12 Million |
+10.98% |
| 2016-12-31 | CN¥2.97 Billion ≈ $435.32 Million |
+16.62% |
| 2015-12-31 | CN¥2.55 Billion ≈ $373.28 Million |
+32.68% |
| 2014-12-31 | CN¥1.92 Billion ≈ $281.35 Million |
+22.75% |
| 2013-12-31 | CN¥1.57 Billion ≈ $229.20 Million |
+16.47% |
| 2012-12-31 | CN¥1.34 Billion ≈ $196.79 Million |
+22.97% |
| 2011-12-31 | CN¥1.09 Billion ≈ $160.03 Million |
+14.60% |
| 2010-12-31 | CN¥954.30 Million ≈ $139.64 Million |
+22.24% |
| 2009-12-31 | CN¥780.68 Million ≈ $114.24 Million |
+7.03% |
| 2008-12-31 | CN¥729.41 Million ≈ $106.73 Million |
+22.22% |
| 2007-12-31 | CN¥596.78 Million ≈ $87.33 Million |
+18.34% |
| 2006-12-31 | CN¥504.30 Million ≈ $73.80 Million |
+4.44% |
| 2005-12-31 | CN¥482.86 Million ≈ $70.66 Million |
-- |
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin… Read more